Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

Wang J, Feng Y, Ji X, Deng G, Leng Y, Liu H.

Bioorg Med Chem. 2013 Dec 1;21(23):7418-29. doi: 10.1016/j.bmc.2013.09.048. Epub 2013 Oct 1.

PMID:
24153396
2.

Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

Ji X, Su M, Wang J, Deng G, Deng S, Li Z, Tang C, Li J, Li J, Zhao L, Jiang H, Liu H.

Eur J Med Chem. 2014 Mar 21;75:111-22. doi: 10.1016/j.ejmech.2014.01.021. Epub 2014 Jan 23.

PMID:
24531224
3.

Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors.

Sharma M, Gupta M, Singh D, Kumar M, Kaur P.

Chem Biol Drug Des. 2013 Aug;82(2):156-66. doi: 10.1111/cbdd.12142. Epub 2013 Jun 29.

PMID:
23581745
4.

(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.

Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.

Eur J Pharmacol. 2011 Mar 25;655(1-3):99-107. doi: 10.1016/j.ejphar.2011.01.010. Epub 2011 Jan 22.

PMID:
21262219
5.

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.

Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Epub 2010 Jun 9. Erratum in: Eur J Pharmacol. 2011 Mar 25;655(1-3):121. multiple author names added.

PMID:
20540938
6.

Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.

Kushwaha RN, Srivastava R, Mishra A, Rawat AK, Srivastava AK, Haq W, Katti SB.

Chem Biol Drug Des. 2015 Apr;85(4):439-46. doi: 10.1111/cbdd.12426. Epub 2014 Oct 16.

PMID:
25216392
7.

Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.

Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Umezome T, Sakurai Y, Sawada N, Tadano J, Sugaru E, Ono M, Hirose Y, Nakahira H.

Bioorg Med Chem. 2015 Feb 15;23(4):779-90. doi: 10.1016/j.bmc.2014.12.051. Epub 2014 Dec 30.

PMID:
25596166
8.

Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.

Ji X, Xia C, Wang J, Su M, Zhang L, Dong T, Li Z, Wan X, Li J, Li J, Zhao L, Gao Z, Jiang H, Liu H.

Eur J Med Chem. 2014 Oct 30;86:242-56. doi: 10.1016/j.ejmech.2014.08.059. Epub 2014 Aug 19.

PMID:
25164763
9.

Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.

Patel BD, Bhadada SV, Ghate MD.

Bioorg Chem. 2017 Jun;72:345-358. doi: 10.1016/j.bioorg.2017.03.004. Epub 2017 Mar 6.

PMID:
28302310
10.

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y.

Bioorg Med Chem. 2012 Oct 1;20(19):5705-19. doi: 10.1016/j.bmc.2012.08.012. Epub 2012 Aug 17.

PMID:
22959556
11.

A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.

Akarte AS, Srinivasan BP, Gandhi S.

Biochem Pharmacol. 2012 Jan 15;83(2):241-52. doi: 10.1016/j.bcp.2011.10.003. Epub 2011 Oct 12.

PMID:
22015634
12.

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.

Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.

Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):209-17. doi: 10.1007/s00210-008-0277-8. Epub 2008 Apr 9.

PMID:
18398600
13.

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.

Vasc Health Risk Manag. 2008;4(4):753-68. Review.

14.

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

Thornberry NA, Gallwitz B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86. doi: 10.1016/j.beem.2009.03.004.

PMID:
19748065
15.

Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.

Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.

Pharmacol Rep. 2009 Sep-Oct;61(5):899-908.

16.

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.

Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S.

Bioorg Med Chem. 2011 Aug 1;19(15):4482-98. doi: 10.1016/j.bmc.2011.06.032. Epub 2011 Jul 7. Erratum in: Bioorg Med Chem. 2011 Sep 15;19(18):5742. Moritou, Yuusuke [corrected to Moritoh, Yusuke].

PMID:
21741847
17.

Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.

Cho TP, Long YF, Gang LZ, Yang W, Jun LH, Yuan SG, Hong FJ, Lin W, Liang GD, Lei Z, Jing LJ, Shen GA, Hong SG, Dan W, Ying F, Ke YP, Ying L, Jun F, Tai MX.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3565-8. doi: 10.1016/j.bmcl.2010.04.120. Epub 2010 May 18.

PMID:
20488702
18.

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.

Gwaltney SL 2nd.

Curr Top Med Chem. 2008;8(17):1545-52. Review.

PMID:
19075765
19.

The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.

Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W.

Eur J Med Chem. 2011 Jan;46(1):71-6. doi: 10.1016/j.ejmech.2010.10.016. Epub 2010 Oct 26.

PMID:
21106276
20.

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Scheen AJ.

Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. Review.

PMID:
20590741

Supplemental Content

Support Center